Manufacturer
NOVO NORDISK A/S
Contents
Liraglutide
Indication
Adult w/ type 2 DM in combination w/ metformin &/or sulfonylurea, metformin & thiazolidinedione or combination therapy w/ metformin & insulin in patient w/ insufficient glycaemic control. Reduction of major adverse CV events (MACE) eg, CV death, non-fatal MI & stroke in adult w/ type 2 diabetes who have established or at high risk for CV disease.
Instruction
SC Initially 0.6 mg daily, may be increased to 1.2 mg after at least 1 wk. Max: 1.8 mg daily.
Drug interaction
Frequent monitoring of INR w/ warfarin & other coumarin derivatives.
Malaysia
